Asia Pacific Digital Pathology Market

The digital pathology market in Asia Pacific is expected to grow from US$ 206.30 million in 2022 to US$ 426.03 million by 2028. It is estimated to grow at a CAGR of 12.8% from 2022 to 2028. 

Use of Digital Pathology in Drug Development to Offer Lucrative Opportunities for Digital Pathology Market in Asia Pacific during 2022–2028 

Drug development is a time-consuming and labour-intensive process. Scientists and pathologists check numerous samples to evaluate how a drug affects a specific tissue or animal. Digital pathology and artificial intelligence (AI) can be employed in this process to improve overall efficiency. Toxicological research generates a vast number of slides, and just adding digital imaging and AI to the workflow may cut down on work hours. This enables pathologists to specifically focus on slides with variations, such as lesions, which are essential to understand drug mechanisms. Moreover, digital image processing enables the extrapolation and memorization of enormous volumes of data from the image than a researcher can do. Furthermore, computers can store everything they have been programmed for, which helps create an information-rich database. Further, the process of collecting, analyzing, and sharing data becomes effortless. Digitized information can be shared with anyone and with anywhere in the world, and pathologists can access the data from remote locations as well. All these aspects result in a structured, effective, high-quality, and focused drug research. Moreover, digital pathology offers pathologists the flexibility to collaborate with anyone on significantly specialized projects, further improving drug discovery in Asia Pacific. 

Pharmaceutical manufacturers are harnessing the benefits of digital pathology in drug development. For instance, in April 2022, GlaxoSmithKline (GSK) recruited PathAI to bring digital pathology AI to cancer and NASH drug development. GSK and PathAI signed a multiyear pact for joining forces to improve the drugmaker's molecule discovery and clinical trial work in NASH and across its oncology portfolio. 

Market Overview 

The Asia Pacific digital pathology market is segmented into China, Japan, India, Australia, South Korea, and the rest of Asia Pacific. The market growth in Asia Pacific is attributed to major factors such as the rising initiatives and support by the government of China, growing cancer cases, increasing focus by industry players in Japan, and developing healthcare infrastructure in India. Digital pathology scanner plays a vital role in the early diagnosis of cancer, and further in its treatment. Images of the cancerous tissues are obtained with the help of digital pathology scanners and analyzed with software. Progress in digital pathology systems enabled the visualization of images and the analysis of these tissues, thereby aiding in cancer treatment. According to Globocan report, in 2020, around 1,028,658 new cancer cases were found in Japan, and 420,124 cancer deaths were recorded in the country. To reduce the number of cancer cases, Japan focuses on improving the early diagnosis of cancer. Furthermore, a few national level conferences are also being arranged in the country to provide the knowledge and lectures on the various cancer diagnosis. For instance, Asia Pacific Summit on Oncology & Cancer was held in May 2017. The aim of this conference was cancer biopsy and imaging tests and diagnostics. Owing to these developments and focus by industry players in Japan the digital pathology market is likely grow in the forecast period. 

Asia Pacific Digital Pathology Market Revenue and Forecast to 2028 (US$ Million)

Get more information on this report Request Free Sample PDF

Asia Pacific Digital Pathology Strategic Insights

Strategic insights for the Asia Pacific Digital Pathology provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Digital Pathology Report Scope

Asia Pacific Digital Pathology Regional Insights

The geographic scope of the Asia Pacific Digital Pathology refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Asia Pacific Digital Pathology Market Segmentation 

The Asia Pacific digital pathology market is segmented into product , type , application and end user. 

Based on product, the market is segmented into scanners, software, storage and communication systems. The scanners segment registered the largest market share in 2022. Based on type, the market is segmented into human pathology, and veterinary pathology. The human pathology segment held the larger market share in 2022. Based on application, the market is segmented into drug discovery, disease diagnostics, teleconsultation, and training & education. The drug discovery segment held the larger market share in 2022. Based on end user, the market is segmented into pharma and biotech companies, hospital, and academic. The pharma and biotech companies segment held the largest market share in 2022. Based on country, the market is segmented into Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific. Japan dominated the market share in 2022. Koninklijke Philips N.V.; Nikon Corporation; PerkinElmer, Inc.; Indica Labs; 3DHISTECH Ltd.; Hamamatsu Photonics K.K.; F. Hoffmann-La Roche Ltd; Visiopharm A/S; Glencoe Software, Inc., and Danaher Corporation. are the leading companies operating in the digital pathology in the region.